These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2340804)

  • 1. [Familial nonneoplastic inappropriate thyrotropin secretion].
    Langer HJ; Leicht E; Koch B; Weinheimer B; Berberich R; Strohfeldt P; Weinges KF
    Dtsch Med Wochenschr; 1990 May; 115(21):813-6. PubMed ID: 2340804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of inappropriate TSH secretion with Triac].
    Lind P; Eber O
    Acta Med Austriaca; 1986; 13(1):13-6. PubMed ID: 3766083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of triiodothyroacetic acid as suppressive treatment of the thyrotropin secretion in thyroid pathology].
    Jaffiol C; Baldet L; Papachristou C; Bringer J
    Presse Med; 1988 Jan; 17(2):57-60. PubMed ID: 2964020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TRIAC (3,5,3'-triiodothyroacetic acid) has parallel effects at the pituitary and peripheral tissue levels in thyroid cancer patients treated with L-thyroxine.
    Mechelany C; Schlumberger M; Challeton C; Comoy E; Parmentier C
    Clin Endocrinol (Oxf); 1991 Aug; 35(2):123-8. PubMed ID: 1934526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hyperthyroidism caused by inadequate TSH secretion].
    Zass R; Steindor U; Wendel U
    Monatsschr Kinderheilkd; 1993 Feb; 141(2):100-2. PubMed ID: 7681522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the metabolic and endocrine effects of 3,5,3'-triiodothyroacetic acid and thyroxine.
    Bracco D; Morin O; Schutz Y; Liang H; Jéquier E; Burger AG
    J Clin Endocrinol Metab; 1993 Jul; 77(1):221-8. PubMed ID: 8325946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in response of thyrotropin to 3,5,3'-triiodothyronine and 3,5,3'-triiodothyroacetic acid in patients with resistance to thyroid hormone.
    Ueda S; Takamatsu J; Fukata S; Tanaka K; Shimizu N; Sakata S; Yamaji T; Kuma K; Ohsawa N
    Thyroid; 1996 Dec; 6(6):563-70. PubMed ID: 9001190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical and hormonal evaluation of recurrence of goiter after thyroidectomy].
    Abeatici S; Palestini N; Sigismondi S
    Minerva Med; 1979 Feb; 70(8):569-74. PubMed ID: 431874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study of the plasma thyrotropin in thyroid diseases].
    Lemarchand-Béraud T; Scazziga BR; Vannotti A
    Schweiz Med Wochenschr; 1966 Jun; 96(22):718-22. PubMed ID: 5988345
    [No Abstract]   [Full Text] [Related]  

  • 10. Triac (3,5,3'-triiodothyroacetic acid) partially inhibits the thyrotropin response to synthetic thyrotropin-releasing hormone in normal and thyroidectomized hypothyroid patients.
    Medeiros-Neto G; Kallas WG; Knobel M; Cavaliere H; Mattar E
    J Clin Endocrinol Metab; 1980 Feb; 50(2):223-5. PubMed ID: 6766460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Discrepancy between clinical status and in vitro thyroid function tests].
    Ríos EP; Dutrem MT; Ruíz E; González P; Valverde C; Maisterrena JA
    Arch Invest Med (Mex); 1974; 5(1):17-22. PubMed ID: 4136340
    [No Abstract]   [Full Text] [Related]  

  • 12. 9 years follow-up of a patient with pituitary form of resistance to thyroid hormones (PRTH): comparison of two treatment periods of D-thyroxine and triiodothyroacetic acid (TRIAC).
    Guran T; Turan S; Bircan R; Bereket A
    J Pediatr Endocrinol Metab; 2009 Oct; 22(10):971-8. PubMed ID: 20020587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thyroid-stimulating hormone suppression therapy for differentiated thyroid cancer: The role for a combined T3/T4 approach.
    Fussey JM; Khan H; Ahsan F; Prashant R; Pettit L
    Head Neck; 2017 Dec; 39(12):2567-2572. PubMed ID: 28960722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current questions of thyroid diseases in childhood].
    Ilyés I
    Orv Hetil; 2011 Apr; 152(16):617-27. PubMed ID: 21454178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients.
    Bartalena L; Martino E; Pacchiarotti A; Grasso L; Aghini-Lombardi F; Buratti L; Bambini G; Breccia M; Pinchera A
    J Clin Endocrinol Metab; 1987 Apr; 64(4):849-55. PubMed ID: 3818906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperthyroidism due to inappropriate secretion of thyroid-stimulating hormone: diagnosis and management.
    Hermus A; Ross H; van Liessum P; Naber A; Smals A; Kloppenborg P
    Neth J Med; 1991 Jun; 38(5-6):193-8. PubMed ID: 1922591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Diagnosis and therapy of patients with simple goiter within the scope of a thyroid gland ambulatory care service].
    Grubeck-Loebenstein B; Vierhapper H; Bratusch-Marrain P; Nowotny P; Waldhäusl W
    Schweiz Med Wochenschr; 1984 May; 114(19):654-9. PubMed ID: 6740282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A case of inappropriate non-neoplastic secretion of TSH treated with bromocriptine.
    Yeğen C; Aktan AO; Saraç AM; Yalin R
    Endocr Regul; 1993 Mar; 27(1):23-5. PubMed ID: 8003703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monitoring TSH levels using the TRH test].
    Alba F; Hawkins F; Díez L; Guitián R; Arnaiz F
    Rev Clin Esp; 1983 Jul 15-31; 170(1-2):51-3. PubMed ID: 6415766
    [No Abstract]   [Full Text] [Related]  

  • 20. Propylthiouracil blocks extrathyroidal conversion of thyroxine to triiodothyronine and augments thyrotropin secretion in man.
    Geffner DL; Azukizawa M; Hershman JM
    J Clin Invest; 1975 Feb; 55(2):224-9. PubMed ID: 805160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.